Literature DB >> 22909322

Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report.

Sergio Raposeiras-Roubín1, Bruno K Rodiño-Janeiro, Beatriz Paradela-Dobarro, Lilian Grigorian-Shamagian, José M García-Acuña, Pablo Aguiar-Souto, Michel Jacquet-Hervet, María V Reino-Maceiras, Ezequiel Alvarez, José R González-Juanatey.   

Abstract

BACKGROUND: Since post-infarction heart failure (HF) determines a great morbidity and mortality, and given the physiopathology implications of advanced glycation end products (AGE) in the genesis of myocardial dysfunction, it was intended to analyze the prognostic value of these molecules in order to predict post-infarction HF development.
METHODS: A prospective clinical study in patients after first acute coronary syndrome was conducted. The follow-up period was consisted in 1 year. In 194 patients consecutively admitted in the coronary unit for myocardial infarct fluorescent AGE levels were measured. The association between glycaemic parameters and the development of post-infarction HF were analyzed in those patients. Finally, we identified the variables with independent predictor value by performing a multivariate analysis of hazard ratio for Cox regression.
RESULTS: Eleven out of 194 patients (5.6%) developed HF during follow-up (median: 1.0 years [0.8 - 1.5 years]). Even though basal glucose, fructosamine and glycated haemoglobin were significant predictive factors in the univariate analysis, after being adjusted by confounding variables and AGE they lost their statistical signification. Only AGE (Hazard Ratio 1.016, IC 95%: 1.006-1.026; p<0,001), together with NT-proBNP and the infarct extension were predictors for post-infarction HF development, where AGE levels over the median value 5-fold increased the risk of HF development during follow-up.
CONCLUSIONS: AGE are an independent marker of post-infarction HF development risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22909322      PMCID: PMC3489693          DOI: 10.1186/1475-2840-11-102

Source DB:  PubMed          Journal:  Cardiovasc Diabetol        ISSN: 1475-2840            Impact factor:   9.951


  37 in total

1.  Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses.

Authors:  Giuseppina Basta; Guido Lazzerini; Marika Massaro; Tommaso Simoncini; Piero Tanganelli; Caifeng Fu; Thomas Kislinger; David M Stern; Ann Marie Schmidt; Raffaele De Caterina
Journal:  Circulation       Date:  2002-02-19       Impact factor: 29.690

2.  Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.

Authors:  Jean-Pierre Bassand; Christian W Hamm; Diego Ardissino; Eric Boersma; Andrzej Budaj; Francisco Fernández-Avilés; Keith A A Fox; David Hasdai; E Magnus Ohman; Lars Wallentin; William Wijns
Journal:  Eur Heart J       Date:  2007-06-14       Impact factor: 29.983

3.  Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.

Authors:  Jasper W L Hartog; Suzan Willemsen; Dirk J van Veldhuisen; Jan L Posma; Leen M van Wijk; Yoran M Hummel; Hans L Hillege; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2011-06-13       Impact factor: 15.534

4.  The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.

Authors:  Francesco Cipollone; Annalisa Iezzi; Maria Fazia; Mirco Zucchelli; Barbara Pini; Chiara Cuccurullo; Domenico De Cesare; Giovanni De Blasis; Raffaella Muraro; Roberto Bei; Francesco Chiarelli; Ann Marie Schmidt; Franco Cuccurullo; Andrea Mezzetti
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

Review 5.  Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.

Authors:  Jasper W L Hartog; Adriaan A Voors; Stephan J L Bakker; Andries J Smit; Dirk J van Veldhuisen
Journal:  Eur J Heart Fail       Date:  2007-12       Impact factor: 15.534

6.  Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.

Authors:  Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Hiroyoshi Inoue; Masayoshi Takeuchi; Seiji Ueda; Kei Fukami; Seiya Okuda; Tsutomu Imaizumi
Journal:  Microvasc Res       Date:  2007-05-18       Impact factor: 3.514

Review 7.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

8.  High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure.

Authors:  Yo Koyama; Yasuchika Takeishi; Takanori Arimoto; Takeshi Niizeki; Tetsuro Shishido; Hiroki Takahashi; Naoki Nozaki; Osamu Hirono; Yuichi Tsunoda; Joji Nitobe; Tetsu Watanabe; Isao Kubota
Journal:  J Card Fail       Date:  2007-04       Impact factor: 5.712

9.  Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells.

Authors:  Ke Yang; Xiao Qun Wang; Yu Song He; Lin Lu; Qiu Jing Chen; Jing Liu; Wei Feng Shen
Journal:  Cardiovasc Diabetol       Date:  2010-10-22       Impact factor: 9.951

10.  RhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular response.

Authors:  Jiping Wang; Hongxia Liu; Bo Chen; Qiang Li; Xuliang Huang; Liqun Wang; Xiaohua Guo; Qiaobing Huang
Journal:  Cardiovasc Diabetol       Date:  2012-01-17       Impact factor: 9.951

View more
  12 in total

Review 1.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.

Authors:  Guanghong Jia; Michael A Hill; James R Sowers
Journal:  Circ Res       Date:  2018-02-16       Impact factor: 17.367

2.  Knockout RAGE alleviates cardiac fibrosis through repressing endothelial-to-mesenchymal transition (EndMT) mediated by autophagy.

Authors:  Lu Zhang; Jiaqi He; Junyan Wang; Jing Liu; Zixin Chen; Bo Deng; Lan Wei; Hanqin Wu; Birong Liang; Huan Li; Yusheng Huang; Lu Lu; Zhongqi Yang; Shaoxiang Xian; Lingjun Wang
Journal:  Cell Death Dis       Date:  2021-05-11       Impact factor: 8.469

3.  Association of subclinical myocardial injury with arterial stiffness in patients with type 2 diabetes mellitus.

Authors:  Kai-Hang Yiu; Chun-Ting Zhao; Yan Chen; Chung-Wah Siu; Yap-Hang Chan; Kui-Kai Lau; Shasha Liu; Chu-Pak Lau; Hung-Fat Tse
Journal:  Cardiovasc Diabetol       Date:  2013-06-22       Impact factor: 9.951

4.  Evolution and bad prognostic value of advanced glycation end products after acute heart failure: relation with body composition.

Authors:  Beatriz Paradela-Dobarro; Ángel Fernández-Trasancos; Diana Bou-Teen; Sonia Eiras; Rocío González-Ferreiro; Rosa M Agra; Alfonso Varela-Román; Ana I Castro-Pais; Marcos C Carreira; Felipe F Casanueva; Ezequiel Álvarez; José R González-Juanatey
Journal:  Cardiovasc Diabetol       Date:  2017-09-15       Impact factor: 9.951

5.  It's all in our skin-Skin autofluorescence-A promising outcome predictor in cardiac surgery: A single centre cohort study.

Authors:  Britt Hofmann; Kristin Anja Gerull; Katja Bloch; Marcus Riemer; Christian Erbs; Anna Fröhlich; Sissy Richter; Martin Ehrhardt; Christopher Zitterbart; Friederike Fee Bartel; Pauline Siegel; Andreas Wienke; Rolf-Edgar Silber; Andreas Simm
Journal:  PLoS One       Date:  2020-06-29       Impact factor: 3.240

6.  Advanced glycation end products in isoproterenol-induced acute myocardial infarction.

Authors:  Tatiana Timercan; Inna Şveţ; Valeriana Pantea; Ala Ambros; Leonid Lîsîi
Journal:  Med Pharm Rep       Date:  2019-07-31

7.  Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway.

Authors:  Qiaojing Qin; Jianying Niu; Zhaoxia Wang; Wangjie Xu; Zhongdong Qiao; Yong Gu
Journal:  Cardiovasc Diabetol       Date:  2013-02-26       Impact factor: 9.951

8.  Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.

Authors:  Yuji Ishibashi; Takanori Matsui; Sayaka Maeda; Yuichiro Higashimoto; Sho-ichi Yamagishi
Journal:  Cardiovasc Diabetol       Date:  2013-08-28       Impact factor: 9.951

9.  Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study.

Authors:  Fumie Ikeda; Yasufumi Doi; Toshiharu Ninomiya; Yoichiro Hirakawa; Naoko Mukai; Jun Hata; Kentaro Shikata; Daigo Yoshida; Takayuki Matsumoto; Takanari Kitazono; Yutaka Kiyohara
Journal:  Cardiovasc Diabetol       Date:  2013-11-07       Impact factor: 9.951

10.  Novel ASK1 inhibitor AGI-1067 improves AGE-induced cardiac dysfunction by inhibiting MKKs/p38 MAPK and NF-κB apoptotic signaling.

Authors:  Zhongwei Liu; Shixiang Zheng; Xi Wang; Chuan Qiu; Yan Guo
Journal:  FEBS Open Bio       Date:  2018-08-17       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.